PGxAI Debuts Deneb, an AI Model Revolutionizing Drug Development for Biopharma

PALO ALTO, Calif., Apr. 5, 2025 — PGxAI, a leader in AI-driven pharmacogenetics, has launched Deneb, its latest model designed to streamline drug development by integrating molecular structures, physicochemical properties, and genetic profiles. Tailored for biopharmaceutical companies and contract research organizations (CROs), Deneb delivers near real-time pharmacogenetic (PGx) recommendations, significantly reducing the time and cost of clinical trials while increasing the likelihood of successful market entry.

By automating the traditionally manual process of PGx guideline creation, Deneb helps researchers pinpoint optimal patient cohorts, refine dosing strategies, and anticipate adverse reactions. The result is a more targeted, data-driven approach that mitigates trial failures and accelerates safer, more effective therapies to market.

“Clinical trial setbacks often stem from the wide variance in individual responses to drugs,” said Dr. Mike Zack, PGxAI co-founder and CEO. “Deneb tackles this challenge by leveraging AI and multi-omics data to rapidly predict how different patient groups will respond to a candidate drug— even before trials begin. This not only reduces costly trial failures but also expedites regulatory approvals.”

Unlike conventional platforms that require months of manual data curation, Deneb processes molecular structure and physicochemical data, cross-referencing them with genetic and multi-omics biomarkers, as well as real-world evidence. This integrated approach provides next-generation insights that refine trial design, de-risk drug pipelines, and shorten overall development timelines.

“Biopharma and CROs today demand more than just incremental improvements — they need scalable, automated tools that drive efficiency and precision,” said Allan Gobbs, PGxAI co-founder and executive chairman. “Deneb is our solution to that challenge. It frees teams from manual labor and empowers them to make decisions based on rigorous, AI-driven analytics.”

Deneb is built on PGxAI’s robust partnerships with leading technology providers such as NVIDIA, InterSystems, Google, and Microsoft, ensuring compatibility with existing R&D workflows. By seamlessly integrating data from multiple sources, Deneb positions PGxAI as a critical ally for pharmaceutical innovators looking to shorten development timelines, reduce adverse events, and deliver cutting-edge therapies to patients worldwide.

About PGxAI

Founded in 2023 and backed by venture capital firm ATEM Capital, PGxAI is at the forefront of AI-driven precision medicine, combining real-world clinical data with advanced genomics research. The company’s proprietary AI platform personalizes drug selection, dosing, and interaction management based on each patient’s unique genetic makeup. Dr. Mike Zack, MD, PhD, a UCSF pharmacogenomics expert, serves as CEO & co-founder, alongside Allan Gobbs, a life sciences investor and executive chairman. PGxAI’s advisory board features experts from Stanford University, Thermo Fisher, and GE Healthcare. By partnering with InterSystems and leveraging cutting-edge cloud and HPC technology from leading providers, PGxAI addresses one of healthcare’s most critical needs: ensuring safe and effective treatments for every individual.